Dr Reddy’s Laboratories launches Toripalimab, the first immuno-oncology drug for nasopharyngeal carcinoma, in India.

Dr. Reddy's Laboratories launches Toripalimab in India, a groundbreaking treatment for metastatic and recurrent ...

Dr. Reddy's launches Loqtorzi biosimilar in India under the brand name Zytorvi for treating adults with recurrent or ...

Dr Reddy's Laboratories has launched toripalimab, an immune oncology drug for adults with recurrent or metastatic ...

In 2023, Dr. Reddy's entered into a license and commercialisation agreement with Shanghai Junshi Biosciences Co. Ltd for ...

Only immuno-oncology drug approved by various regulatory authorities around the world such as the USFDA, DCGI, EMA, MHRA, ...

With this launch, India has become the third country in the world, after China and the US, to receive access to this ...

Dr. Reddy's Laboratories Ltd. (RDY) said that it has launched Toripalimab in India, the first and only immuno-oncology drug approved ...

In 2023, Dr Reddy's signed a licensing and commercialisation agreement with Shanghai Junshi Biosciences for Toripalimab ...

Dr. Reddy's Laboratories has announced the launch of Toripalimab in India. This drug is designed to treat adults suffering ...

Dr. Reddy’s Laboratories has launched Toripalimab, a New Biological Entity (NBE) in the domestic market. “The launch of ...